Cornelius J R, Soloff P H, Perel J M, Ulrich R F
Western Psychiatric Institute and Clinic, University of Pittsburgh, PA 15213.
Psychopharmacol Bull. 1990;26(1):151-4.
Borderline personality disorder (BPD) is defined by many of the symptoms associated with serotonin dysregulation, including affective lability, suicidal behaviors, and impulsive aggression, providing an ideal clinical model for studying the treatment of these serious disorders. The recent development of selective serotonin re-uptake inhibitors such as fluoxetine makes it possible to study the role of serotonin in the etiology of affective and behavioral dyscontrol in BPD. In this preliminary medication trial, 5 patients with BPD were treated openly with 20 mg to 40 mg of fluoxetine for 8 weeks, with weekly ratings of symptoms. The findings from this work suggested efficacy for fluoxetine in treating the depressive and impulsive symptoms of patients with BPD. The findings were mixed concerning the efficacy of fluoxetine in treating the hostility and psychotic symptoms of BPD. No evidence for effectiveness was found in the treatment of the anxiety, phobic anxiety, or interpersonal sensitivity of BPD.
边缘型人格障碍（BPD）由许多与血清素调节异常相关的症状所定义，包括情感不稳定、自杀行为和冲动攻击，这为研究这些严重障碍的治疗提供了一个理想的临床模型。像氟西汀这样的选择性血清素再摄取抑制剂的最新发展，使得研究血清素在BPD情感和行为失控病因中的作用成为可能。在这项初步药物试验中，5名BPD患者接受了20毫克至40毫克氟西汀的开放治疗，为期8周，并每周对症状进行评分。这项研究的结果表明氟西汀在治疗BPD患者的抑郁和冲动症状方面具有疗效。关于氟西汀治疗BPD的敌意和精神病性症状的疗效，研究结果不一。在治疗BPD的焦虑、恐惧性焦虑或人际敏感性方面，未发现有效性证据。
